Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ex vivo expanded CD34+ hematopoietic stem cells
- Development stage
- Phase 1
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ExHSC refers to **ex vivo expanded CD34+ hematopoietic stem cells**. These are autologous or allogeneic hematopoietic stem cells isolated from sources such as bone marrow, peripheral blood, or umbilical cord blood, then expanded outside the body (ex vivo) to increase their number before administration to patients. This approach aims to enhance engraftment and hematopoietic recovery, especially in settings such as stem cell transplantation or cellular therapies for malignancies or genetic diseases. As a cell therapy, exHSC does not correspond to a single chemical entity or small molecule, but rather to a cellular product prepared under specific laboratory and clinical protocols.
- Other names
- exHSCex vivo expanded CD34+ hematopoietic stem cells
Beyond the preview
Go deeper on ex vivo expanded CD34+ hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ex vivo expanded CD34+ hematopoietic stem cells.